Covered recipient · General Payments record
DAVID A LYNCH
Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology
General Payments · PY2018–2024
$223,119.72
- Reported across 97 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $38,219.00 | 14 |
| Food and Beverage | $228.72 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $29,779.00 | 12 |
| Merck Sharp & Dohme Corporation | $5,490.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,070.72 | 2 |
| Boehringer Ingelheim International GmbH | $108.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | $108.00 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118139206 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $120.72 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118139208 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,950.00 | 07/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1118139210 | CMS |
| Daiichi Sankyo Inc. | $4,025.50 | 01/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450504 | CMS |
| Daiichi Sankyo Inc. | $2,594.75 | 02/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450482 | CMS |
| Daiichi Sankyo Inc. | $945.75 | 03/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450490 | CMS |
| Daiichi Sankyo Inc. | $2,061.25 | 04/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450488 | CMS |
| Daiichi Sankyo Inc. | $727.50 | 05/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450492 | CMS |
| Daiichi Sankyo Inc. | $3,128.25 | 06/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450496 | CMS |
| Daiichi Sankyo Inc. | $727.50 | 07/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450484 | CMS |
| Daiichi Sankyo Inc. | $3,516.25 | 08/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450500 | CMS |
| Daiichi Sankyo Inc. | $2,837.25 | 09/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450498 | CMS |
| Daiichi Sankyo Inc. | $1,333.75 | 10/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450494 | CMS |
| Daiichi Sankyo Inc. | $4,243.75 | 11/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450502 | CMS |
| Daiichi Sankyo Inc. | $3,637.50 | 12/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089450486 | CMS |
| Merck Sharp & Dohme LLC | $5,490.00 | 06/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141634503 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.